ClinicalTrials.gg
CompletedNCT02320708Updated Dec 3, 2021

Study of Acetaminophen (ACE) in Post-operative Dental Pain

A Phase 2 interventional study of Acetaminophen (ACE) (1000 mg) and Commercial ACE (1000 mg) in Dental Pain, sponsored by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.. Completed at 1 site in United States. Open to participants aged 17 Years to 50 Years. Per ClinicalTrials.gov, last updated 2021-12-03.

Sponsored by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. (formerly part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
17 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Toothache with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Toothache · United States.

Enrollment
19th of 50
240 · median 194
Started
2014
with 4 others
Phase 2
20 of 54
none open now
Registered
34th of 54
by date

Among the 54 studies in Toothache with a site in United States, this one is the 19th largest by enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2014, is one of 20 in phase 2, and was the 34th registered.

Toothache

142 studies on the registry are indexed under Toothache; 28 are open to participants now.

Browse Toothache studies →

Open to participants now

6 of the 54 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 17 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Toothache with a site in United States, or all of them as a file.
02

Study summary

This is a dental pain study evaluating the efficacy and safety of a single dose of test acetaminophen (ACE) (1000 mg) compared to commercial acetaminophen (1000 mg), ibuprofen (IBU) (400 mg), and placebo over a 6 hour period. Subjects will undergo dental extraction of three or four third molars.

03

Conditions studied

  • Dental Pain

Browse trials for

Keywords

  • Molar,third; Teeth,wisdom; Pain, Postoperative; Dental Surgery; Third molar extraction
04

Who can participate

Ages eligible
17 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are 17 to 50 years of age
  2. Weigh 100 lbs or greater and (BMI) 18 to 30 (inclusive)
  3. Dental extraction of three or four third-molars.
  4. Experience moderate to severe pain after extraction of third molars

Exclusion criteria

Exclusion Criteria:

  1. Currently pregnant (or planning to be pregnant) or nursing a baby
  2. Known allergy to acetaminophen (ACE) or non-steroidal anti-inflammatory drugs (NSAIDs)
  3. Inability to swallow whole large tablets or capsules
  4. Have other conditions that the investigator feels may impact subject's safety and/or the integrity of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Test Acetaminophen (ACE) (1000 mg) and placebo

    Drug: Acetaminophen (ACE) (1000 mg) · Drug: Placebo

  • Active comparator
    Commerical ACE (1000 mg) and placebo

    Drug: Commercial ACE (1000 mg) · Drug: Placebo

  • Active comparator
    Commerical Ibuprofen (IBU) (400 mg) and placebo

    Drug: Commercial Ibuprofen (IBU) (400 mg) · Drug: Placebo

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 2 Test ACE 500 mg tablets taken orally one time

  • DrugCommercial ACE (1000 mg)

    2 ACE 500 mg caplets taken orally one time

  • DrugCommercial Ibuprofen (IBU) (400 mg)

    2 IBU 200 mg soft-gels taken orally one time

  • DrugPlacebo

    2 placebo caplets for acetaminophen taken orally one time

  • DrugPlacebo

    2 placebo soft-gels for ibuprofen taken orally one time

  • DrugPlacebo

    2 placebo tablets for Test acetaminophen taken orally one time

06

What researchers measure

Primary outcomes

  1. Time weighted sum of pain intensity difference from 0-6 hours (SPID 0-6)

    Time weighted sum of pain intensity difference scores from baseline over 6 hours. Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 6 Hours

Secondary outcomes

  1. Time weighted sum of pain intensity difference from 0-4 hours (SPID 0-4)

    Time weighted sum of pain intensity difference scores from baseline over 4 hours. Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 4 Hours

  2. Time to meaningful pain relief

    Minutes until meaningful pain relief are achieved. Stopwatch is started after the subject takes the study medication. The subjects are instructed to stop the stopwatch when the relief from the starting pain is meaningful to them.

    Time frame: Within 6 Hours

  3. Time to first perceptible pain relief

    Minutes until first perceptible pain relief is achieved. Stopwatch is started after the subject takes the study medication. The subject is instructed to stop the stopwatch when they first begin to feel any pain relief.

    Time frame: Within 6 Hours

  4. Time to confirmed first perceptible relief

    Minutes until confirmed first perceptible pain relief are achieved. Stopwatch is started after the subject takes the study medication. The subject is instructed to stop the stopwatch when they first begin to feel any pain relief. The first perceptible pain relief is confirmed if the subject also stopped the second stopwatch indicating meaningful pain relief.

    Time frame: Within 6 Hours

  5. Time weighted sum of pain relief from 0-4 (TOTPAR 0-4)

    Time weighted sum of pain relief scores over four hours. Pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 4 hours

  6. Time weighted sum of pain relief from 0-6 (TOTPAR 0-6)

    Time weighted sum of pain relief scores over six hours. Pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 6 hours

  7. Duration of relief after dosing (time to rescue analgesic)

    Minutes until rescue medication is given

    Time frame: 6 Hours

  8. Proportion of subjects taking a rescue analgesic by 6 hours

    Percentage of subjects using rescue medication through six hours

    Time frame: 6 Hours

  9. Subject Global Evaluation assessed at hour 6 or at time of rescue

    Patient assessment of the pain medication - number of subjects rating the medication they received as a pain reliever on a score of 0-4, where 0=poor, 1=fair, 2=good, 3=very good, 4=excellent

    Time frame: 6 hours

  10. Pain relief (PAR) scores at 0.25 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 0.25 Hours

  11. Pain relief (PAR) scores at 0.5 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 0.5 Hours

  12. Pain relief (PAR) scores at 0.75 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 0.75 Hours

  13. Pain relief (PAR) scores at 1 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 1 Hours

  14. Pain relief (PAR) scores at 1.25 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 1.25 Hours

  15. Pain relief (PAR) scores at 1.5 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 1.5 Hours

  16. Pain relief (PAR) scores at 2 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 2 hoursH

  17. Pain relief (PAR) scores at 3 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 3 Hours

  18. Pain relief (PAR) scores at 4 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 4 Hours

  19. Pain relief (PAR) scores at 5 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 5 Hours

  20. Pain relief (PAR) scores at 6 Hours

    Pain relief scores at each assessment time point - pain relief was evaluated using a 0-10 pain relief numerical rating scale (PR-NRS) where 0 = no relief and 10 = complete relief

    Time frame: 6 Hours

  21. Pain intensity difference (PID) at 0.25 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 0.25 Hours

  22. Pain intensity difference (PID) at 0.5 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 0.5 Hours

  23. Pain intensity difference (PID) at 0.75 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 0.75 Hours

  24. Pain intensity difference (PID) at 1 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 1 Hours

  25. Pain intensity difference (PID) at 1.25 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 1.25 Hours

  26. Pain intensity difference (PID) at 1.5 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 1.5 Hours

  27. Pain intensity difference (PID) at 2 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 2 Hours

  28. Pain intensity difference (PID) at 3 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 3 Hours

  29. Pain intensity difference (PID) at 4 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 4 Hours

  30. Pain intensity difference (PID) at 5 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 5 Hours

  31. Pain intensity difference (PID) at 6 Hours

    Pain intensity difference (PID) from baseline at each assessment time point - Pain intensity was evaluated using a 0-10 pain intensity numerical rating scale (PI-NRS) where 0 = no pain and 10 = very severe pain

    Time frame: 6 Hours

07

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Apr 2015, 3 months.

Of 10 phase 2 interventional studies under Toothache, half reached primary completion within 3 months of starting (the median); a quarter within 3 and three quarters within 5. This study's 3 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2014
First posted
Dec 19, 2014
StartActual
Dec 31, 2014
Primary completionActual
Apr 30, 2015
CompletionActual
Apr 30, 2015
Results delay requested
Apr 29, 2016
Last update
Dec 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02320708
Responsible party
Sponsor
First posted
Dec 19, 2014
Start date
Dec 31, 2014
Primary completion
Apr 30, 2015
Completion
Apr 30, 2015
Last update
Dec 3, 2021

Study contacts

Study Director
study director · McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion